Natixis’s Clovis Oncology, Inc. CLVS Stock Holding History

Natixis’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500,000	Closed	-$600K	–	1407
2022 Q3	$600K	Buy	+500,000	New	+$779K	﹤0.01%	864
2021 Q4	–	Sell	-50,000	Closed	-$223K	–	1393
2021 Q3	$223K	Sell	50,000 -60,700	-55%	-$292K	﹤0.01%	1136
2021 Q2	$642K	Buy	+110,700	New	+$649K	﹤0.01%	673
2021 Q1	–	Sell	-20,196	Closed	-$97K	–	1216
2020 Q4	$97K	Sell	20,196 -1,069,240	-98%	-$5.41M	﹤0.01%	1016
2020 Q3	$6.35M	Buy	+1,089,436	New	+$6.52M	0.05%	238
2018 Q2	–	Sell	-7,459	Closed	-$394K	–	1016
2018 Q1	$394K	Buy	+7,459	New	+$435K	﹤0.01%	696
2017 Q4	–	Sell	-3,426	Closed	-$282K	–	1251
2017 Q3	$282K	Buy	+3,426	New	+$272K	﹤0.01%	942

Other funds holding CLVS

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Natixis's CLVS Position: Q4 2022 in Review

Natixis sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 500,000 shares — an estimated $600K sold.

Natixis first reported a position in CLVS in Q3 2017 and held it in 7 quarters. The position peaked at $6.35M in Q3 2020. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Natixis reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Natixis sold 500,000 Clovis Oncology, Inc. shares in Q4 2022, an estimated $600K.
Natixis first reported a position in Clovis Oncology, Inc. in Q3 2017 and held it in 7 quarters.
Natixis's Clovis Oncology, Inc. position peaked at $6.35M in Q3 2020.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Natixis's 13F filing for Q4 2022, filed 13 Feb 2023.